**3. β-conglycinin**

Ferreira et al conducted a study to investigate the effect of daily oral administration of soy‐ bean β-conglycinin (7S protein) (300 mg/kg/day) alone and in conjunction with the hypolipi‐ demic drugs fenofibrate (30 mg/kg/day) and rosuvastatin (10 mg/kg/day) in hypercholesterolemic rats for 28 days. The data reveal that conglycinin exhibits effects simi‐ lar to those of fenofibrate and rosuvastatin in the control of plasma cholesterol, HDL-C and triglycerides, and suggests that the association of soybean β-conglycinin with rosuvastatin changes the action of the drug in cholesterol homeostasis [3].
